Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Vir Biotechnology, Inc. (VIR) reported a Q4 loss of $0.76 per share, which was better than the Zacks Consensus Estimate of a $0.85 loss. However, the company lagged in revenue estimates.

February 27, 2025 | 12:00 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Vir Biotechnology reported a Q4 loss of $0.76 per share, better than the expected $0.85 loss, but missed revenue estimates.
The better-than-expected EPS loss is a positive sign, but missing revenue estimates could offset this. The stock may see mixed reactions as investors weigh these factors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100